Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06148623 · ClinicalTrials.gov registry record · NA
Clinical Performance Testing of Philips FAST SpO2 With Masimo Pulse Oximetry Sensors Across Skin Pigmentation
A NA study of Healthy, sponsored by Masimo Corporation.
- Completed
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT06148623: Completed NA study of Healthy, sponsored by Masimo Corporation.
NCT06148623 is a NA study of Healthy that has completed, run by Masimo Corporation. The registered enrollment target is 70 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06148623, a NA study of Healthy, has completed, sponsored by Masimo Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
Validate the performance of Philips FAST SpO2 with Masimo Pulse Oximetry Sensors in determining functional arterial oxygen saturation (SpO2) using arterial saturation (SaO2) as a reference in the range of 70-100% in subjects of varying skin pigmentation.
Primary Outcome
The SpO₂ accuracy of Philips FAST SpO₂ with Masimo Pulse Oximeter Sensor (RD SET® Adt) was determined by calculating the accuracy root mean-squared (ARMS) difference between the measured values (SpO₂) to the reference values (SaO₂) in accordance with ISO-80601-2-61. ARMS is a standard statistical method used in pulse oximetry performance evaluations to quantify the overall accuracy of a device. Arms= √(∑(i=1 to n) ((SpO₂\_i-SaO₂\_i )\^2 ))/n. Participants in this arm could receive one or more
Conditions Studied
Interventions
- DEVICE Philips FAST SpO2 with Masimo Pulse Oximetry Sensors
Study Locations (1)
California
- Masimo Corporation - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-11-13 |
| Est. Completion | 2025-01-14 |
| Phase | NA |
What the finished NCT06148623 record still lists
NCT06148623 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Philips FAST SpO2 with Masimo Pulse Oximetry Sensors is the first listed.
NCT06148623 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06148623 about?
NCT06148623 is a clinical study titled "Clinical Performance Testing of Philips FAST SpO2 With Masimo Pulse Oximetry Sensors Across Skin Pigmentation". Validate the performance of Philips FAST SpO2 with Masimo Pulse Oximetry Sensors in determining functional arterial oxygen saturation (SpO2) using arterial saturation (SaO2) as a reference in the range of 70-100% in subjects of varying skin pigmentation.
What is the current status of trial NCT06148623?
This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2023-11-13. Estimated completion is 2025-01-14.
What conditions does trial NCT06148623 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT06148623?
The interventions under investigation include: Philips FAST SpO2 with Masimo Pulse Oximetry Sensors (DEVICE).
Who is sponsoring clinical trial NCT06148623?
This trial is sponsored by Masimo Corporation, which has 96 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06148623 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06148623's enrollment target sits among peer trials
70 325th of 1090 higher than 759 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
-
Oxalate and Citrate in Humans - Response to Citrate
RECRUITING · NA
-
CArdioMEtabolic Function and Reserve Capacity in Healthy Adults: The CAMERA Study
RECRUITING · NA
-
Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia
RECRUITING · NA
-
Medical Illustration Design Characteristic Evaluation
RECRUITING · NA
-
Sodium vs Potassium Education to Improve Vascular Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI